Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.7 CHF | -0.55% | -11.99% | -1.42% |
Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
Apr. 19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.42% | 1.01B | B- | ||
-29.72% | 15.63B | B- | ||
-22.89% | 12.43B | B | ||
-24.53% | 6.57B | B | ||
+15.23% | 6.46B | C | ||
-11.39% | 6.04B | C+ | ||
-1.90% | 4.63B | D- | ||
+60.00% | 4.61B | C | ||
-5.94% | 3.94B | B | ||
-9.36% | 3.51B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSE Stock
- Ratings DocMorris AG